logo

Coherus Oncology

Nasdaq • CHRS • US19249H1032

Market Closed

About this data: CHRS short interest, cost to borrow and days to cover

This page tracks how heavily Coherus Oncology (Nasdaq:CHRS) is being shorted: ORTEX's daily short interest estimate, the cost to borrow the shares, utilization of the lendable supply and days to cover, next to the official exchange-reported figure.

Short interest
The number of shares that have been sold short and not yet bought back, usually shown as a percentage of free float (the shares available to trade). ORTEX estimates it every day from securities-lending data, instead of waiting for exchange reports that are published only twice a month and about two weeks late.
Cost to borrow
The annualised fee a short seller pays to borrow the shares, as a percentage of the position's value. A rising cost to borrow means lendable shares are getting scarce and holding the short is getting more expensive.
Utilization
The share of the lendable supply of a stock that is currently on loan. Close to 100% means almost no shares are left to borrow.
Days to cover
Short interest divided by average daily trading volume: roughly how many days of normal trading it would take for every short seller to buy back their shares.
Exchange-reported short interest
The official figure published by the exchange or regulator (in the US, FINRA twice a month). It is accurate but delayed, which is the gap the ORTEX daily and intraday estimates fill.

Source: ORTEX. Some figures are limited on the free view; live data and full history are part of ORTEX Advanced.

CHRS key data

Coherus Oncology (Nasdaq: CHRS) has a market capitalization of $148.12M. Last close $1.01 (as of 2026-10-21); 52-week range $0.94 to $2.62. ORTEX data as of 2026-10-19: short interest is 15.08% of free float, 12.3 days to cover and the average cost to borrow is 0.82%.